 |
| Main Menu | News By Date | News By Supplier | News By Category | About Us |
|
FINDING MAY LEAD TO NEW THERAPIES
“Our results offer the first evidence of dopamine terminal injury, specifically injury to dopamine transporters, in HIV dementia patients,” says Brookhaven physician Gene-Jack Wang, the study’s lead author. “This suggests that a decrease in transporters may contribute to the disease process. We believe our findings also indicate a new direction for treatment.” “This study clearly demonstrates that HIV infection damages dopamine-associated brain cells, and provides a pathway for developing more effective treatments,” says National Institute on Drug Abuse Director Nora Volkow, co-investigator, who worked on the study while at Brookhaven Lab. Using positron emission tomography, a brain-scanning technique, Wang and colleagues looked at the brains of 15 HIV-positive study volunteers, some of whom had symptoms of dementia, and 13 HIV-negative volunteers. The purpose of the scans was to determine the presence of dopamine transporters and dopamine receptors. Dopamine transporters, found on the terminals of some brain cells (neurons), recycle dopamine, a brain chemical that sends signals between the cells. Dopamine receptors are “docking ports” on the receiving neurons. Dopamine is associated with pleasure and reward and is also essential for movement; low levels are found in conditions such as Parkinson’s disease. Decreased dopamine transporters represent neuron damage and lower levels of functional dopamine neurons, as well as decreases in the release of dopamine. PET scans showing dopamine transporters (top row) and dopamine D2 receptors (bottom row) in a 47-year-old control subject (left), a 48-year-old HIV subject without dementia (middle), and a 52-year-old HIV subject with dementia (right), at the level of the basal ganglia. The images are scaled with respect to the maximum value obtained in the control subject and presented using the rainbow scale (red color, high value, violet, low value). The HIV subjects with dementia showed significantly lower dopamine transporter availability bilaterally compared to the seronegative controls in the putamen and in the ventral striatum, but only mild and non-significant decreases in the caudate. The non-demented HIV patients, however, showed no significant decreases in dopamine transporters in the basal ganglia. Dopamine D2 receptor availability did not differ between the HIV and the control subjects in any of the regions. Prior to brain scanning, each volunteer was given an injection containing a radiotracer, a radioactive chemical “tag” designed to “light up” activated areas of the brain. The PET camera picks up the radioactive signal and measures the level and location of the tracer. Two hours after the first scan, each volunteer was given a second radiotracer, and his/her brain was scanned again. The first scan looked specifically for the presence of dopamine receptors, and the second searched for dopamine transporters. The researchers found that HIV-positive patients with, but not those without dementia, had significantly lower dopamine transporter levels in the putamen and ventral striatum, the brain regions containing the most transporters, compared with HIV-negative volunteers. Higher levels of HIV virus correlated with lower transporter levels in the caudate, part of the striatum, and in the putamen. Dopamine receptor levels showed only mild decreases in HIV-positive volunteers. “These findings suggest that HIV patients with dementia may benefit from dopamine-enhancing treatments, especially those patients with more severe cognitive motor deficits,” says Wang. “Studies have shown, however, that some of these agents may actually exacerbate HIV-induced neurotoxicity, but antioxidants may block this mechanism. Further studies should focus on adjunctive approaches combining drugs in both classes.” “Viral suppression seems to correlate with less injury to the dopamine system,” Wang continues. “Because of this correlation, future studies should look at whether viral suppression after antiretroviral treatment can lead to recovery of deficits in the dopamine system.”
|
| ©2008 New Materials International |